Johnson & Johnson and Bayer AG failed to win the backing of a U.S. advisory panel to expand the use of their blood-thinner Xarelto, raising another challenge in the companies’ repeated effort to sell the drug to a bigger group of heart patients.
GlaxoSmithKline Plc’s Avandia was linked to heart attacks and other cardiovascular complications in two new studies that the authors say should prompt U.S. regulators to pull the diabetes drug from the market.
A U.S. advisory panel’s call for stronger warnings about heart risks tied to GlaxoSmithKline Plc ’s diabetes drug Avandia may further erode sales that had already been dropping over the last two years.
Roche Holding AG is planning a final-stage trial of a drug that taps into a gene mutation to lower cholesterol and heart attack risk beyond what statins such as Pfizer Inc.’s $9.6 billion-selling Lipitor can do.
Boston Scientific Corp.’s Watchman device, designed to help prevent strokes in patients with an erratic heartbeat, was safer than previously thought in a second study requested by U.S. regulators, researchers said.
Amgen Inc., the world’s largest biotechnology company, is developing a new anti-cholesterol medicine by 2015 that it sees as its best shot to offset reduced sales when its popular anemia drugs lose exclusivity.